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Background: Intravascular papillary endothelial hyperplasia (IPEH) is a benign intravascular process with features
mimicking other benign and malignant vascular proliferations. IPEH lesions predominate in the head-neck region
and the extremities. The characteristic histomorphological feature of IPEH is a papillary structure covered with
hyperplastic endothelial cells within the vascular lumen. It is critical that this clinically benign lesion should not be
mistaken for well-differentiated vascular tumors. In addition to the characteristic histological features, other useful
diagnostic features included the intra-luminal location of the lesion, an intimate association with the organizing
thrombus, the absence of necrosis, cellular pleomorphism, and mitotic activity. In addition, immunohistochemistry
may indicate the vascular origin and proliferative index. In this study, we evaluated histomorphological and
immunohistochemical findings (CD31, CD34, FVIII, type IV collagen, SMA, MSA, CD105, and Ki-67 staining) of ten
IPEH cases.
Methods: Ten IPEH cases were re-examined for a panel of histomorphological and immunohistochemical features.
CD31, CD34, FVIII, Type IV collagen, SMA and MSA antibodies utilized for immunohistochemical analysis.
The histomorphological and immunohistochemical findings were evaluated by two independent pathologists using
light microscopy.
Results: All ten cases involved intraluminal lesions with characteristic features of IPEH. All ten cases (100%) were
stained positive for CD31 and CD34. The degree of staining with FVIII, type IV collagen, SMA, and MSA was variable.
Conclusion: In this series of specimens, CD31 and CD34 were the most sensitive markers indicating the vascular
origin of the lesion. Staining for the other vascular markers (FVIII, type IV collagen, SMA and MSA) was variable.
Different maturation degrees of lesions may account for the variation in immunohistochemical staining. Few
previous investigations evaluated a wide range of antigen panels in IPEH sections. In our opinion, the evaluation of
immune markers in a larger sample set will reveal new features in the maturity and developmental pathogenesis of
vascular lesions and angiogenesis. IPEH is a benign lesion, which must be differentiated from malignant tumors
such as angiosarcoma and Kaposi’s sarcoma. Improved definition of IPEH lesions using immunohistochemical
markers may enhance the ability to differentiate between various vascular lesions.
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Intravascular papillary endothelial hyperplasia (IPEH) is a
benign, non-neoplastic intravascular lesion. The clinical
features of IPEH may mimic other benign lesions includ-
ing mucocele, pyogenic granuloma, and hemangioma, as
well as malignant neoplasms such as angiosarcoma and
Kaposi’s sarcoma [1-7]. IPEH is alternately referred to as
Masson’s tumor, intravascular angiomatosis, and intra-
vascular vegetating hemangioendothelioma by the many
investigators who have struggles to define this unique
structure [2,3]. The lesion features associated with the
disease was first defined by Masson in 1923 and was
termed IPEH in 1976 by Clearkin and Enzinger [1,8].
IPEH lesions frequently develop in the extremities, in-
cluding the head, neck, and body, but are most promin-
ent in the digits and within blood vessels throughout the
body [1,2,9]. In rare circumstances, atypical IPEH lesions
have been observed in the abdominal organs or in intra-
cranial aneurysms [9,10].
The primary histologic feature of IPEH is the formation
of papillary structures lined by hyperplastic endothelial
cells in the vascular lumen [1-5,11]. IPEH is closely asso-
ciated with thrombus formation in many cases. Previous
reports have suggested that unique variation in thrombus
organization contributes to IPEH [1,3,4,12], however the
molecular basis for the development of IPEH in thrombus
tissue has not been determined.
The differentiation of benign biological IPEH lesions
from angiosarcoma is critical. Benign IPEH lesions are
completely cured by local excision, while angiosarcoma
is a malignant tumor that is capable of metastasis and
may not be fully eradicated by localized surgical removal
[2,4]. Several additional criteria are important in differ-
entiating IPEH lesions from malignant angiosarcoma in-
cluding intraluminal lesion origin, minimal necrosis,
close association with organized thrombus, and lack of
pleomorphic and mitotic activity in cells [1-4]. Although
IPEH is mostly an intravascular lesion, extravascular
hematoma organization features may also be present
[13]. The demonstration of vascular origin and prolifera-
tive index by immunohistochemistry may contribute to
the accurate differential diagnosis of IPEH [4].
In the present study, we investigate the morphological
and immunohistochemical staining characteristics (CD31,
C34, FVIII,Type 4 collagen, SMA,MSA, CD105 and KI-67)
of 10 IPEH cases. Previous studies have used more limited
immunological panels in similar analyses. In our opinion,
the evaluation of immune markers in a wider series will re-
veal the new insights regarding the developmental stages of
vascular lesions and angiogenesis. IPEH is a benign lesion
that must be accurately differentiated from malignant
angiosarcoma. Improved definition of IPEH lesions using
immunohistochemical markers may enhance the ability to
differentiate betweenvarious vascular lesions.Materials and methods
Hematoxylin-eosin stained sections of ten IPEH cases pre-
senting at our hospital were re-examined for histomorpho-
logical featuresusing lightmicroscopy.
Four micron thick sections were prepared from paraffin
blocks and mounted on to poly-L-lysine coated slides. Sec-
tions were deparaffinized overnight and then heated at
60°C to 37°C in an oven. The sections were subsequently
subjected to xylene for 5 minutes three times, grade alco-
hol, and distilled water 3 times for 5 minutes. Antigen re-
trieval was performed using 10 mM citrate buffer at
pH 6.0. The sections were boiled in distilled water using
the equivalent of a 750-watt microwave oven for 5 minutes
at a temperature interval of 20 minutes. After 20 min at
room temperature, the samples were washed twice in
phosphate buffer saline PBS. Sections were dampened in a
drying environment of 25°C by dropping 3% hydrogen per-
oxide on to the sections for 15 minutes to block endogen-
ous peroxidase activity. The primary antibody was applied
without additional washing.
The following primary antibody preparations were added
toeachof thesections: 1/100dilutedCD31,clone:PECAM-1
(Genemed, USA); 1/100 diluted CD34, clone: BI-3C5
(Invitrogen); ready-to-use FVIII clone: 86PECAM-1
(Labvision, Fremont, CA); ready-to-use type 4 collagen
clone: COL-94 (Biogenex, CA), 1/50 diluted SMA clone:
ASM-1 (Leica, UK); 1/100 diluted MSA, clone: HHF35
(Genemed, USA); ready-to-use CD105, clone: SN6h
(Neomarkers, Fremont, CA); 1/100 diluted Ki-76, clone:
MM1(Leica,UK).Allsectionswereincubatedwithprimary
antibody for 1 hour. The sections were washed twice in
PBS for 3 minutes. After 15 minutes secondary antibody
incubation, with the sections were washed with PBS be-
fore the application of streptavidin for 15 minutes. With
the sections were again washed with PBS for 10 minutes
before the application of AEC chromogen. The sections
were again washed with distilled water and counter-
stained with hematoxylin Mayer and covered with water-
based medium.
In each case, the vessels of the surrounding tissue were
used as internal controls for CD31, C34, FVIII, Type 4
collagen, SMA and MSA; tonsil tissue was used as a
control for CD105 and Ki-67.
Results
The clinical characteristics of the IPEH cases including
age, sex, localization, presentation and size is shown in de-
tail in Table 1. The age of the patients ranged between 23
and 71, with a mean age of 40. Three of the patients were
male (30%), and seven patients were female (70%). Five of
the cases (50%) involved upper extremity localization,
while five cases were localized in the head-neck region
(50%). The largest lesion was 1.5 cm in diameter, while the
smallest lesion had a diameter of 0.6 cm. The average
Table 1 Evaluation of IPEH cases in terms of age, sex,
localization, presentation and size
Case Age Gender Localization Presentation Size (cm)
1 35 male scalp mass 1,1 cm
2 33 female Orbital region mass 1,1 cm
3 45 female hand mass 1,0 cm
4 40 female neck mass 0,6 cm
5 51 male hand mass 0,7 cm
6 71 female finger mass 0,6 cm
7 27 female hand mass 1,1 cm
8 23 female scalp mass 0,6 cm
9 47 female finger mass 0,8 cm
10 28 male scalp mass 1,2 cm
Figure 2 Papillary endothelial structures (H&E × 200).
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firmed intravascular localization and demonstrated spe-
cific IPEH histomophological characteristics (Figures 1
and 2). Six cases were of associated with an organized
thrombus (Figure 3). The presence of papillary structures
lined by a single row of endothelial cells (Figure 4), absence
of pleomorphism, mitosis, and necrosis in vascular lumen
was confirmed in all ten cases.
The immunohistochemical staining distribution is shown
in Table 2. In 5 cases (50%); CD31, CD34, FVIII, Type 4
collagen, SMA and MSA markers was observed as positive.
The remaining cases demonstrated variable staining for
these markers. Staining by CD31 and CD34 was present in
all 10 cases (100%) (Figures 5 and 6) while staining by FVIII
was observed in 6 cases (60%). Type 4 collagen staining
was present in 8 cases (80%). SMA and MSA co-staining
occurred in 8 cases, with only 2 cases (20%) having no
reactivity for these immune markers. None of the cases
stained positive for CD105. The proliferative index was less
than 8% (1%-8%) for the cases examined.Figure 1 Intravascular Papillar Endothelial with organized
thrombus in the lumen of a blood vessel (H&E × 40).Discussion and conclusion
Basic histological feature of IPEH is the formation of
papillary structures lined by hyperplastic endothelial
cells in the vascular lumen [1-5,11]. Frequently, IPEH
has a close association with thrombus. Several reports
have proposed that there is a special variation in the
organization procedure of thrombus [1,3,4,12], however,
the basis for the development of the lesion in thrombus
has not been determined. The developmental procedure
of the lesion takes place in several steps [14].
Normally older trombi tend to become organized. This
refers to ingrowth of endothelial cells, smooth muscle
cells, and fibroblasts into the fibrin-rich thrombus. In
time, capillary channels are formed, which may anasto-
mose to create conduits from one and of the thrombus
to the other, reestablishing to some extent the continuity
of the original lumen. This recanalization may eventually
convert the thrombus into a vascularised mass of con-
nective tissue, which is incorporated as a subendothelialFigure 3 IPEH; papillary structures in the vessel (H&E × 40).
Figure 4 Fibrous stroma and the surrounding flattened
endothelial cells in a single row, (H&E × 400).
Figure 5 Endothelial cells stained with CD34 (×400).
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the mesenchimal cells, only a fibrous lump may remain
to mark the original thrombus site [15].
Similar to thrombus organization and recanalization,
the developmental pathogenesis of IPEH lesion formation
occurs in several steps [14]. Embedment of endothelial
cells within the thrombus characterizes early stage le-
sions. Subsequently, the proliferating endothelial cells
segregate the collagenase-digested thrombus into irregu-
lar clumps from which papillary structures will develop.
In the final stage, papillae combine and form anastomos-
ing vascular structures.
Some investigators have proposed that the developing
thrombusservesasamatrixfortheingrowthofpapillarystruc-
tures [16]. Ultrastructurally, these papillary structures closely
resemble granulation tissue, suggesting a reparative origin
[17]. In addition, endothelium-lining cells appear to originate
in histiocytes and the exuberant endothelial proliferationTable 2 Immunohistochemical staining distribution
Case CD31* CD34* FVIII** Type IV Colla
Case 1 + + + +
Case 2 + + + +
Case 3 + + - +
Case 4 + + + +
Case 5 + + - -
Case 6 + + + +
Case 7 + + - +
Case 8 + + - -
Case 9 + + + +
Case 10 + + + +
* They stained the immature endothelium which covers multiple small papillary stru
** Positive staining was seen in mature lesions.
***Positive staining in the basement membrane of the endothelial vessel wall.
****Positive staining was seen only surrounding wall of mature well formed vesselsinvolves an autocrine loopof endothelial secretions including
basic fibroblastgrowthfactor [18].Reportsofoccasionalcases
that did not involve thrombosis in addition to reports of the
presence of a lymphatic counterparthave led someauthors to
supportMasson’s original theory that IPEH is a benign tumor
marked by primary endothelial proliferation and secondary
thrombus formation[19].
IPEH is a benign behavioral vascular lesion that must be
accurately differentiated from malignant angiosarcoma
and other vascular tumours [1-5,20]. Correct diagnosis
consists of careful histomorphological examination in con-
junction with IHC staining.
Monoclonal antibodies directed against CD34 and
CD31 have yielded insights into the nature of vascular
tumors. These antigens are not endothelial cell specific,
but they are widely expressed by vascular endothelium,
particularly under pathological conditions [21].
CD34 is a cell surface protein that is expressed by human
hematopoietic cells of both the myeloid and lymphoidgen*** SMA**** MSA**** CD105 Ki67
+ + - ≤1%
+ + - ≤1%
+ + - ≤2%
+ + - ≤8%
- - - ≤5%
+ + - ≤7%
+ + - 2%
- - - 3%
+ + - 3%
+ + - 1%
ctures (lining endothelial cells), and also mature well formed vessels.
.
Figure 6 Endothelial cells stained with CD31 (×400).
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early events of blood cell differentiation and modulate ad-
hesion in both endothelial cells and hematopoietic progeni-
tor cells [22].
CD31 is a trans-membrane glycoprotein expressed by
platelets, monocytes, granulocytes, B-cells, certain sub-
sets of leukocytes, and endothelial cells [22].
We observed CD31 and CD34 staining in all 10 cases
(100%). In our opinion both CD31 and CD34 stain IPEH
endothelium with high intensity and are highly effective in
establishing the vascular root of the lesion. In our study
CD31 and CD34 labeled all maturity levels of lesions. They
stained diffuse strongly the immature endothelium which
covers multiple small papillary structures (lining endothe-
lial cells), and also mature well formed vessels,
Factor VIII-related antigen (FVIII) is a protein that is
synthesized by endothelial cells and is an excellent marker
of endothelial differentiation [9].
Tosios et al. have described the presence of FVIII-
related antigen in the final stages of IPEH organization
[23], and the presence of FVIII-related antigen is strong
evidence of IPEH.
Flope et al. observed that well differentiated capillaries
strongly express factor VIII, but is not expressed in the
endothelial cells lining small slit-like, sieve-like vascular
spaces and spindle-shaped tumor cells. Jones et al.,
Mentzel et al. and Wilken et al. have reported similar
observations [21,24-26].
In our study 6 cases (60%) exhibited FVIII staining,
similar to the findings of Albrecht and Kahn [12]. In their
study, Albrecht and Kahn presented maturity-dependent
variation in FVIII staining of IPEH lesions. FVIII positive
staining was seen only in mature lesions.
In addition to endothelial cells, IPEH lesions consist of
basal membrane and pericytes associated with vascular
proliferation and immune markers. Effective identi-fication of these components using IHC may improve
IPEH diagnosis. Multiple reports have established the
use of a panel of immune markers to demonstrate the
vascular root of IPEH [4,5,12,21,27]. We evaluated Type
4 collagen, SMA, and MSA staining in addition to the
established endothelial-specific markers in this study,
observing variation in staining intensity in many of the
cases examined. This variability may be related to the
stage of IPEH lesion development.
Soares et al. has described Collagen type IV staining in
the basement membrane of the endothelial vessel wall,
and cells surrounding the vessel wall express SMA [5].
We also examined the immune marker CD105.
CD105 (endoglin) is a membrane-bound homodimer
expressed in angiogenic endothelial cells that has re-
cently been associated with tumor angiogenesis. CD105
has an important role in angiogenesis and is essential
for the proliferation of endothelial cells during the ac-
tive phase of angiogenesis. Endothelial cells are the
principal source of CD105, however other cells types in-
cluding vascular smooth muscle cells, fibroblasts, and
macrophages express CD105 to a lesser extent [28]. The
expression of CD105 is a prominent feature of newly
formed blood vessels, but is minimally expressed in fully
formed vessels. The expression of CD105 in blood ves-
sels surrounding IPEH lesions suggests a potential role
for CD015 in tumor angiogenesis. Non-neoplastic tis-
sues with increased angiogenic activity, such as the de-
veloping embryo and during wound remodeling, can
also express limited amounts of CD105 [28-33].
Soares et al. [5] found that proliferative endothelial
cells are negative for CD105 in IPEH tissues, suggesting
that IPEH differs from the reactive processes occurring
in pyogenic granulomas in which all cells are positive for
CD105 expression. IPEH tissues are unlikely to be com-
prised of proliferative angiogenic tissues.
We investigated whether this new endothelial marker,
CD105, was not present in 10 cases of IPEH. None of the
tissues evaluated demonstrated significant CD105 stain-
ing, consistentwith thework done by Soares et al. [5].
Few previous studies of IPEH immunohistochemical
staining have utilized a wide panel of immune markers.
In our opinion, the evaluation of novel immune markers,
primarily FVIII, in a wider series will enhance our un-
derstanding of vascular lesions and angiogenesis.
In conclusion, IPEH is a benign behavioral vascular le-
sion that must be accurately differentiated from malig-
nant angiosarcoma through careful histomorphological
examination in conjunction with immunohistochemical
staining.
CD31 and CD34 are the most effective markers for
identification of the vascular root, whereas FVIII, Type 4
collagen, SMA and MSA staining vary widely between
individual cases.
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